Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels

Blood. 2014 Nov 6;124(19):2983-6. doi: 10.1182/blood-2014-07-584953. Epub 2014 Sep 15.


The extended use of brentuximab-vedotin was reported for CD30(+) nonanaplastic peripheral T-cell lymphomas (PTCLs) with promising efficacy. CD30 status assessment is thus a critical factor for therapeutic decision, but the reliability of immunohistochemistry (IHC) in evaluating its expression remains to be defined. This prompted us to investigate the correlation between semiquantitative CD30 protein assessment by IHC and messenger RNA (mRNA) assessment by microarrays in a cohort of 376 noncutaneous PTCLs representative of the main entities. By IHC, CD30 expression was heterogeneous across and within entities and significantly associated with large tumor cell size. In addition to 100% anaplastic large-cell lymphomas, 57% of other PTCL entities were CD30-positive at a 5% threshold. CD30 protein expression was highly correlated to mRNA levels. mRNA levels were bimodal, separating high from low CD30-expressing PTCL cases. We conclude that IHC is a valuable tool in clinical practice to assess CD30 expression in PTCLs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brentuximab Vedotin
  • Drug Monitoring / methods
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Immunoconjugates / therapeutic use
  • Immunohistochemistry / methods*
  • Immunohistochemistry / standards
  • Ki-1 Antigen / genetics*
  • Ki-1 Antigen / metabolism*
  • Lymphoma, T-Cell, Peripheral / drug therapy
  • Lymphoma, T-Cell, Peripheral / genetics*
  • Lymphoma, T-Cell, Peripheral / metabolism*
  • RNA, Messenger / metabolism
  • Reproducibility of Results


  • Immunoconjugates
  • Ki-1 Antigen
  • RNA, Messenger
  • Brentuximab Vedotin